XML 14 R5.htm IDEA: XBRL DOCUMENT v3.26.1
CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (Unaudited) - USD ($)
$ in Thousands
Total
Common Shares
Additional Paid in Capital
Accumulated Other Comprehensive Loss
Accumulated Deficit
Prefunded Warrant [Member]
Prefunded Warrant [Member]
Additional Paid in Capital
Beginning balance (in shares) at Oct. 31, 2024   50,976,676          
Beginning balance at Oct. 31, 2024 $ 272,612 $ 509,811 $ 18,950 $ (1,419) $ (254,730)    
Exercise of stock options (in shares)   884          
Exercise of stock options 1 $ 1          
Share-based compensation expense 1,809   1,809        
Other comprehensive income (loss) 144     144      
Net loss (24,616)       (24,616)    
Ending balance (in shares) at Jan. 31, 2025   50,977,560          
Ending balance at Jan. 31, 2025 249,950 $ 509,812 20,759 (1,275) (279,346)    
Beginning balance (in shares) at Oct. 31, 2024   50,976,676          
Beginning balance at Oct. 31, 2024 272,612 $ 509,811 18,950 (1,419) (254,730)    
Net loss (50,431)            
Ending balance (in shares) at Apr. 30, 2025   51,070,851          
Ending balance at Apr. 30, 2025 227,291 $ 510,121 23,300 (969) (305,161)    
Beginning balance (in shares) at Jan. 31, 2025   50,977,560          
Beginning balance at Jan. 31, 2025 249,950 $ 509,812 20,759 (1,275) (279,346)    
Exercise of stock options (in shares)   93,291          
Exercise of stock options 200 $ 309 (109)        
Share-based compensation expense 2,650   2,650        
Other comprehensive income (loss) 306     306      
Net loss (25,815)       (25,815)    
Ending balance (in shares) at Apr. 30, 2025   51,070,851          
Ending balance at Apr. 30, 2025 227,291 $ 510,121 23,300 (969) (305,161)    
Beginning balance (in shares) at Oct. 31, 2025   52,018,658          
Beginning balance at Oct. 31, 2025 167,710 $ 513,281 27,349 (888) (372,032)    
Exercise of stock options (in shares)   117,868          
Exercise of stock options 277 $ 440 (163)        
Share-based compensation expense 2,803   2,803        
Stock Issued During Period, Shares, New Issues   14,852,940          
Stock Issued During Period, Value, New Issues 118,271 $ 118,271          
Issuance of warrants 411   411     $ 21,780 $ 21,780
Other comprehensive income (loss) 46     46      
Issuance of warrants in connection with Amended Term Loan expense 411   411     $ 21,780 $ 21,780
Net loss (29,752)       (29,752)    
Ending balance (in shares) at Jan. 31, 2026   66,989,466          
Ending balance at Jan. 31, 2026 281,546 $ 631,992 52,180 (842) (401,784)    
Beginning balance (in shares) at Oct. 31, 2025   52,018,658          
Beginning balance at Oct. 31, 2025 $ 167,710 $ 513,281 27,349 (888) (372,032)    
Exercise of stock options (in shares) 117,868            
Net loss $ (59,979)            
Ending balance (in shares) at Apr. 30, 2026   66,989,466          
Ending balance at Apr. 30, 2026 255,168 $ 631,995 56,325 (1,141) (432,011)    
Beginning balance (in shares) at Jan. 31, 2026   66,989,466          
Beginning balance at Jan. 31, 2026 281,546 $ 631,992 52,180 (842) (401,784)    
Exercise of stock options 3 $ 3          
Share-based compensation expense 4,145   4,145        
Other comprehensive income (loss) (299)     (299)      
Net loss (30,227)       (30,227)    
Ending balance (in shares) at Apr. 30, 2026   66,989,466          
Ending balance at Apr. 30, 2026 $ 255,168 $ 631,995 $ 56,325 $ (1,141) $ (432,011)